--- title: "Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/286420443.md" description: "Rallybio Corporation's major shareholder, Adar1 Capital Management, acquired 800 shares at $13.83 each, totaling $11,064, increasing their stake by 0.10%. This follows a series of recent purchases, including 50,000 shares at $14.00 each. Despite the insider buying activity, Rallybio reported a quarterly loss of $1.46 per share, missing analyst expectations, and currently holds an average Sell rating. The stock is trading near a 52-week high, with a market cap of $75.91 million and a PE ratio of -5.61." datetime: "2026-05-14T12:52:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286420443.md) - [en](https://longbridge.com/en/news/286420443.md) - [zh-HK](https://longbridge.com/zh-HK/news/286420443.md) --- # Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares ## Key Points - **Rallybio major shareholder Adar1 Capital Management** bought 50,000 shares on May 11 at an average price of $14.00, spending about $700,000 and increasing its stake by 6.41%. - Adar1 also made several recent purchases, including 120,804 shares on May 4 and 35,101 shares on May 5, signaling continued insider buying activity in RLYB. - Rallybio shares were trading near a 52-week high, but the company recently reported a quarterly loss of $1.46 per share, missing analyst expectations, and the stock currently carries an average **Sell** rating. Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 800 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average cost of $13.83 per share, with a total value of $11,064.00. Following the acquisition, the insider owned 830,584 shares in the company, valued at $11,486,976.72. This trade represents a 0.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC. Adar1 Capital Management, Llc also recently made the following trade(s): - On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The shares were purchased at an average cost of $14.00 per share, with a total value of $700,000.00. - On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The shares were purchased at an average cost of $14.00 per share, with a total value of $491,414.00. - On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were purchased at an average cost of $13.97 per share, with a total value of $1,687,631.88. ## Rallybio Trading Up 2.3% Shares of Rallybio stock opened at $14.35 on Thursday. The company has a 50 day moving average of $9.70 and a 200-day moving average of $6.93. Rallybio Corporation has a 1-year low of $2.16 and a 1-year high of $15.31. The company has a market cap of $75.91 million, a PE ratio of -5.61 and a beta of -1.10. * * * * * * Rallybio (NASDAQ:RLYB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.26). Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.The firm had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.23 million. ## Analyst Ratings Changes A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rallybio in a report on Friday, May 8th. Wall Street Zen raised shares of Rallybio to a "hold" rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Rallybio presently has an average rating of "Sell". **Check Out Our Latest Report on Rallybio** ## Hedge Funds Weigh In On Rallybio Several institutional investors and hedge funds have recently added to or reduced their stakes in RLYB. XTX Topco Ltd increased its position in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after acquiring an additional 38,205 shares during the period. Susquehanna International Group LLP raised its stake in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after acquiring an additional 113,031 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after acquiring an additional 2,996 shares during the last quarter. Citadel Advisors LLC raised its stake in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors own 90.34% of the company's stock. ## Rallybio Company Profile (Get Free Report) Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options. Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. ## See Also - Five stocks we like better than Rallybio - Affirm's Google Deal Aims for Your Wallet - Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar - Oklo Stock Could Be Ready for Another Massive Run - D-Wave Earnings Looked Weak, But Investors May Be Missing This _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at Rallybio? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Rallybio and related companies. From Our Partners One coin wired into Elon's vision The Kevin Warsh Fed takeover is here. And he's brought a thesis with him that almost nobody is talking about. ... Crypto 101 Media Trump's gold order: the announcement they won't put on the front page On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group Iran's New Leader Just Said Something That Should Terrify Every American Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ... American Alternative Before you buy SpaceX shares, consider this alternative approach SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin... Weiss Ratings Collect $1,170 a month from silver I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens... Investors Alley Is this AI lab Elon’s SpaceX lifeline? Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ... Chaikin Analytics SpaceX just filed. The clock is ticking. Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re... The Oxford Club Millionaire trader: “Buy this before May 15.” Hedge fund legend Larry Benedict - who beat the S&P 500 by 18 times in 2025 and generated $95 million for clie... Brownstone Research ### Related Stocks - [RLYB.US](https://longbridge.com/en/quote/RLYB.US.md) ## Related News & Research - [Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/289222291.md) - [Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 10,200 Shares of Stock](https://longbridge.com/en/news/287138492.md) - [Fox Run Management L.L.C. Buys New Stake in SM Energy Company $SM](https://longbridge.com/en/news/289305245.md) - [Potomac Capital Management Inc. Purchases Shares of 20,000 Bank of America Corporation $BAC](https://longbridge.com/en/news/289308604.md) - [Oscar Health, Inc. $OSCR Shares Acquired by Geode Capital Management LLC](https://longbridge.com/en/news/289160259.md)